Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.71 |
| ▸ | C1R | P00736 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5921024 | 0.87 | ELANE (0.76) | ELANEC1RPKM | |
| SCHEMBL5921264 | 0.87 | ELANE (0.56) | ELANEC1RPKM | |
| SCHEMBL914656 | 0.86 | ELANE (0.76) | ELANEC1R | |
| SCHEMBL8006834 | 0.84 | C1R (0.81) | ELANEC1R | |
| SCHEMBL914260 | 0.83 | KLK3 (0.54) | ELANEC1RPKM | |
| SCHEMBL5778141 | 0.82 | C1R (0.73) | ELANEC1RPKM | |
| SCHEMBL5921486 | 0.81 | PKM (0.57) | ELANEC1RPKM | |
| SCHEMBL4192197 | 0.78 | C1R (0.71) | ELANEC1R | |
| SCHEMBL5921076 | 0.77 | C1R (0.65) | ELANEC1RPKM | |
| SCHEMBL14262960 | 0.76 | ELANE (0.63) | ELANEC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6180625-B1 | MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 2001-01-30 | — | — | US | claimed |
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| CN-100518740-C | Pharmaceutical use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2009-07-29 | — | — | CN | disclosed |
| US-7339057-B2 | Method for preparing fused oxazinones from ortho-amino aromatic carboxylic acid and carboxylic acid in the presence of a sulfonyl chloride and pyridine | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-7339057-B2 | Method for preparing fused oxazinones from ortho-amino aromatic carboxylic acid and carboxylic acid in the presence of a sulfonyl chloride and pyridine | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-7276601-B2 | Method and preparing fused oxazinones | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276601-B2 | Method and preparing fused oxazinones | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| CN-1802160-A | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2006-07-12 | — | — | CN | disclosed |
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | NPS PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| CN-1708306-A | Quinazolinone compounds as calcilytics | NPS PHARMA INC (US) | 2005-12-14 | — | — | CN | disclosed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| US-6180625-B1 | MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | ELANE 353/4885C1R 202/4885PKM 1104/4885 |
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | CALCR, CALCRL, CASR | ELANE 3009/4885C1R 1605/4885PKM 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.